Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Cash from Operations (2016 - 2025)

Utah Medical Products (UTMD) has 16 years of Cash from Operations data on record, last reported at 3878000.0 in Q3 2025.

  • For Q3 2025, Cash from Operations rose 0.57% year-over-year to 3878000.0; the TTM value through Sep 2025 reached 14152000.0, down 17.85%, while the annual FY2024 figure was 14831000.0, 33.44% down from the prior year.
  • Cash from Operations reached 3878000.0 in Q3 2025 per UTMD's latest filing, up from 2873000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 6915000.0 in Q1 2023 and bottomed at 2762000.0 in Q2 2024.
  • Average Cash from Operations over 5 years is 4772473.68, with a median of 4987000.0 recorded in 2021.
  • Peak YoY movement for Cash from Operations: soared 37.04% in 2023, then plummeted 44.92% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 4987000.0 in 2021, then rose by 13.9% to 5680000.0 in 2022, then fell by 6.13% to 5332000.0 in 2023, then tumbled by 44.92% to 2937000.0 in 2024, then soared by 32.04% to 3878000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 3878000.0 in Q3 2025, 2873000.0 in Q2 2025, and 4464000.0 in Q1 2025.